• Skip to primary navigation
  • Skip to main content
  • Skip to footer
JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

  • Who We Are
  • Patient Commitment
  • Global Expansion
  • Pipeline
  • J-Brain Cargo Technology

JCR Pharmaceuticals
Together We Soar.

JCR is pleased to highlight our clinical achievements with nine presentations at WORLDSymposium 2021.

Download an overview of our WORLDSymposium abstracts Learn More About WORLDSymposium

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and persistence – means that the work we do benefits all our stakeholders, including employees, partners, and patients.

We continue to build upon our 45-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies.

Play Video

Patient Commitment

We Stand with Patients

At JCR, we are united with the patients, families, and communities we serve. We seek to understand their needs and develop new medicines with significant and meaningful benefits. We created JCR to improve the lives of people with rare and genetic diseases, and we remain driven by this common purpose.

We recognize the limitations of available therapies for rare and genetic diseases, including lysosomal storage disorders such as MPS Type I, MPS Type II, and MPS Type III. Many people with these conditions experience severe complications of the central nervous system (CNS). Developmental delays, impaired cognition, and an overall poor prognosis can negatively impact independence and quality of life for both patients and caregivers.

Together, we are working towards better outcomes for patients.

Read a message from our CEO

Doctor checking child's heartbeat
Doctor checking child's heartbeat

Global Expansion

We continue to build upon our history of success in Japan while expanding our global footprint by developing first-in-class and best-in-class therapies, and further expanding our capabilities in manufacturing and R&D.

Trials Beginning in 2021

The United States

Europe

Latin America

Recent News Milestones

September 2020 Received Orphan Drug Designation for JR-141 (MPS II) in Japan
Filed for marketing approval of JR-141 (MPS II) in Japan
October 2020 First patient dosed in phase 1/2 of global clinical trial of JR-171 (MPS I)
December 2020 Filed for marketing authorization of JR-141 (MPS II) in Brazil

Learn More about our recent news milestones

View our WORLDSymposium 2021 Abstracts

This year, JCR Pharmaceuticals is attending the virtual 17th annual WORLDSymposium, an annual conference dedicated to lysosomal storage disorders, Feb. 8-12. We will have nine presentations at the event.

Download an overview of our WORLDSymposium abstracts

Development Pipeline – January 2021

Target Indicators Basic Research Animal
Model Study
Process Development* Including development of industrial scale process, testing method and formulation Preclinical Clinical (Global) Application
for marketing approval
Target Indicator: MPS II - Hunter JR-141 (Japan and Brazil)
Development Stage: Application for marketing approval
JR-141 (Japan and Brazil)
Target Indicator: MPS II - Hunter JR-141 (U.S., EU, and Latin America)
Development Stage: Clinical (Global)
JR-141 (U.S., EU, and Latin America)
Target Indicator: MPS II - Hurler JR-171
Development Stage: Clinical (Global)
JR-171
Target Indicator: Pompe disease JR-162
Development Stage: Preclinical
JR-162
Target Indicator: MPS IIIA - Sanfilippo A JR-441
Development Stage: Preclinical
JR-441
Target Indicator: MPS VII - Sly JR-443
Development Stage: Process Development* Including development of industrial scale process, testing method and formulation
JR-443
Target Indicator: MPS IIB - Sanfilippo B JR-446
Development Stage: Process Development* Including development of industrial scale process, testing method and formulation
JR-446
Target Indicator: GM1 gangliosidosis
Development Stage: Animal Model Study
Target Indicator: Fucosidosis
Development Stage: Animal Model Study
Target Indicator: GM2 gangliosidosis - Tay-Sachs disease
Development Stage: Animal Model Study
Target Indicator: Krabbe disease
Development Stage: Animal Model Study
Target Indicator: Metachromatic leukodystrophy
Development Stage: Animal Model Study
Target Indicator: CLN1 - Batten disease infantile
Development Stage: Animal Model Study
Target Indicator: CLN2 - Batten disease late infantile
Development Stage: Animal Model Study
Target Indicator: Gaucher disease
Development Stage: Animal Model Study
Target Indicator: Niemann-Pick disease
Development Stage: Animal Model Study
Target Indicator: ɑ-Mannosidosis
Development Stage: Animal Model Study

*Including development of industrial scale process, testing method and formulation

J-Brain Cargo® Technology

Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients’ independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of lysosomal storage disorders by delivering the enzyme to both the body and the brain.

Discover More About our R&D Capabilities

Footer

Please visit jcrpharm.co.jp or email ir-info@jcrpharm.co.jp for more information.